GSK’s Shingrix prefilled syringe presentation approved in Canada
GSK Canada announced that Health Canada has approved a prefilled syringe presentation of Shingrix (Recombinant Zoster Vaccine) for the prevention of shingles. The new presentation eliminates the need to reconstitute separate vials before administration, simplifying the vaccination process for healthcare professionals. The prefilled syringe maintains the same approved indications as the current formulation and is expected to become available across Canada in early 2027.
Novartis’ RHAPSIDO (remibrutinib) approved in Canada for chronic spontaneous urticaria
Novartis Canada announced that Health Canada has approved RHAPSIDO (remibrutinib tablets) for the treatment of adults with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1-antihistamine therapy. RHAPSIDO is the first oral Bruton’s tyrosine kinase (BTK) inhibitor approved in Canada for CSU and offers a targeted treatment option to help reduce the signs and symptoms of the disease. The approval expands therapeutic options for Canadians living with inadequately controlled CSU.
Bausch Health’s ELIDEL (pimecrolimus) cream reimbursed under Alberta’s public drug plan
Bausch Health Canada announced that ELIDEL (pimecrolimus) cream is now reimbursed under Alberta’s public drug plan for eligible patients with mild-to-moderate atopic dermatitis. The listing expands public access to the non-steroidal topical treatment for eligible patients who meet coverage criteria, joining several other provincial drug plans that already reimburse ELIDEL. The reimbursement is expected to improve access to treatment for Albertans living with atopic dermatitis.
Biocon receives Health Canada approval for YESINTEK (ustekinumab) autoinjector pen
Biocon announced that Health Canada has approved the YESINTEK (ustekinumab) autoinjector pen in 45 mg/0.5 mL and 90 mg/mL presentations. The autoinjector provides an additional administration option for the YESINTEK® biosimilar, supporting the treatment of approved autoimmune diseases. The approval expands patient choice and enhances access to a more convenient self-administration option for Canadians receiving ustekinumab therapy.
Pfizer’s PREVNAR 20 selected for Québec’s publicly funded pediatric pneumococcal immunization program
Pfizer Canada announced that PREVNAR 20™ (20-valent pneumococcal conjugate vaccine) has been selected for Québec’s publicly funded pediatric pneumococcal immunization program. Since May 2026, the vaccine has been offered routinely to eligible infants across the province, expanding protection against 20 pneumococcal serotypes. The program is expected to enhance the prevention of invasive pneumococcal disease and improve access to broader pneumococcal protection for children in Québec.
